Acorda Therapeutics Inc (ACOR)

25.15
0.20 0.80
NASDAQ : Health Care
Prev Close 24.95
Open 24.60
Day Low/High 24.24 / 25.14
52 Wk Low/High 23.85 / 43.63
Volume 180.98K
Avg Volume 533.00K
Exchange NASDAQ
Shares Outstanding 46.07M
Market Cap 1.23B
EPS 0.30
P/E Ratio 83.47
Div & Yield N.A. (N.A)

Latest News

Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's

Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Volume: Acorda Therapeutics (ACOR)

Strong On High Volume: Acorda Therapeutics (ACOR)

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a strong on high relative volume candidate

September 16th Options Now Available For Acorda Therapeutics (ACOR)

September 16th Options Now Available For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options begin trading today, for the September 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new September 16th contracts and identified one put and one call contract of particular interest.

Acorda To Host Conference Call To Discuss Second Quarter 2016 On July 28, 2016

Acorda To Host Conference Call To Discuss Second Quarter 2016 On July 28, 2016

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2016 financial results and pipeline updates on Thursday, July 28 at 8:30 a.

Acorda Appoints Burkhard Blank, M.D., As Chief Medical Officer (CMO)

Acorda Appoints Burkhard Blank, M.D., As Chief Medical Officer (CMO)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Burkhard Blank, M.

Biotie Therapies Corp. Announces That The Delisting Of Its American Depositary Shares From NASDAQ Global Select Market Has Become Effective

Biotie Therapies Corp. Announces That The Delisting Of Its American Depositary Shares From NASDAQ Global Select Market Has Become Effective

Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (" Biotie" or the " Company") announces that the voluntary delisting of its American Depositary Shares (" ADSs") from the NASDAQ Global Select Market (" Nasdaq US") became...

Acorda Presents Phase 1 Data On CVT-427 For Acute Treatment Of Migraine At 58th Annual Scientific Meeting Of The American Headache Society

Acorda Presents Phase 1 Data On CVT-427 For Acute Treatment Of Migraine At 58th Annual Scientific Meeting Of The American Headache Society

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced pharmacokinetic (PK) data from a Phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption...

Acorda Therapeutics To Present At The 37th Annual Goldman Sachs Global Healthcare Conference

Acorda Therapeutics To Present At The 37th Annual Goldman Sachs Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).

Acorda To Discontinue Development Of PLUMIAZ For Treatment Of Epilepsy Seizure Clusters

Acorda To Discontinue Development Of PLUMIAZ For Treatment Of Epilepsy Seizure Clusters

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will discontinue development of PLUMIAZ TM (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people...

Biotie Therapies Corp. To Delist Its American Depositary Shares From The Nasdaq Global Select Market

Biotie Therapies Corp. To Delist Its American Depositary Shares From The Nasdaq Global Select Market

Biotie Therapies Corp. ("Biotie") today announces that its Board of Directors has resolved to voluntarily delist its American Depositary Shares ("ADSs"), each representing 80 Biotie ordinary shares with no nominal value...

Acorda Therapeutics Named One Of The Best Places To Work For In New York

Acorda Therapeutics Named One Of The Best Places To Work For In New York

Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the best companies to work for in New York, based on an independent survey by the Best Companies Group (BCG).

Acorda Therapeutics (ACOR) Highlighted As Today's Perilous Reversal Stock

Acorda Therapeutics (ACOR) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "perilous reversal" (up big yesterday but down big today) candidate

Acorda Therapeutics (ACOR) Is Today's Dead Cat Bounce Stock

Acorda Therapeutics (ACOR) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a weak on high relative volume candidate

Acorda Therapeutics To Present At Two Investor Conferences In May

Acorda Therapeutics To Present At Two Investor Conferences In May

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during May.

Acorda Provides Financial And Pipeline Update For First Quarter 2016

Acorda Provides Financial And Pipeline Update For First Quarter 2016

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the first quarter ended March 31, 2016.

Acorda Announces Results From Phase 2b Clinical Trial Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Movement Disorders

Acorda Announces Results From Phase 2b Clinical Trial Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Movement Disorders

Data from the Phase 2b clinical trial of CVT-301, published this week in the peer-reviewed journal Movement Disorders, showed that people with Parkinson's disease (PD) experiencing OFF periods and who were treated with...

Completion Of Acorda Therapeutics' Voluntary Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. And Matters Related Thereto

Completion Of Acorda Therapeutics' Voluntary Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. And Matters Related Thereto

On 11 March 2016, Acorda Therapeutics, Inc. (Nasdaq:ACOR) (" Acorda" or the " Offeror") commenced a voluntary public tender offer to purchase all of the issued and outstanding shares (" Shares"), American Depositary Shares...

Acorda To Host Conference Call To Discuss First Quarter 2016 On April 28, 2016

Acorda To Host Conference Call To Discuss First Quarter 2016 On April 28, 2016

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its first quarter 2016 financial results and pipeline updates on Thursday, April 28, at 8:30 a.

Final Results Of Acorda Therapeutics' Voluntary Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. And Commencement Of A Subsequent Offer Period

Final Results Of Acorda Therapeutics' Voluntary Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. And Commencement Of A Subsequent Offer Period

On 11 March 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (" Acorda" or the " Offeror") commenced a voluntary public tender offer to purchase all of the issued and outstanding shares (" Shares"), American Depositary Shares...

'Mad Money' Lightning Round: UnitedHealth May Be the Dow's Best Stock

'Mad Money' Lightning Round: UnitedHealth May Be the Dow's Best Stock

Cramer says buy Mattel under $30 but avoid Acorda Therapeutics.

Jim Cramer's 'Mad Money' Recap: These Stocks Are New-High Winners

Jim Cramer's 'Mad Money' Recap: These Stocks Are New-High Winners

Cramer says the market's diverse leadership is a very bullish sign.

Acorda Therapeutics Announces Preliminary Tender Offer Results And Acceptance Of The Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. Tendered In Tender Offer

Acorda Therapeutics Announces Preliminary Tender Offer Results And Acceptance Of The Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. Tendered In Tender Offer

On 11 March 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (" Acorda" or the " Offeror") commenced a voluntary public tender offer to purchase all of the issued and outstanding shares (" Shares"), American Depositary Shares...

Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy Of Neurology (AAN) Annual Meeting

Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy Of Neurology (AAN) Annual Meeting

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that data from a Phase 2b clinical trial of CVT-301 in Parkinson's disease (PD) will be featured during the Movement Disorders Invited Science Session at the...

Acorda Therapeutics Supplements The Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 22 March 2016

Acorda Therapeutics Supplements The Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies Corp. On 22 March 2016

As announced on 10 March 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (" Acorda" or the " Offeror") has on 11 March 2016 commenced a voluntary public tender offer (the " Tender Offer") to purchase all of the issued and...

Acorda Wins Federal Circuit Appeal Allowing AMPYRA® Patent Litigation To Continue In Delaware District Court

Acorda Wins Federal Circuit Appeal Allowing AMPYRA® Patent Litigation To Continue In Delaware District Court

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that Acorda's Abbreviated New Drug Application (ANDA) litigation...

Acorda Therapeutics Supplements Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies On 18 March 2016

Acorda Therapeutics Supplements Tender Offer Document Relating To The Voluntary Public Tender Offer For All Of The Issued And Outstanding Shares, American Depositary Shares, Stock Options, Share Units And Warrants In Biotie Therapies On 18 March 2016

As announced on 10 March 2016, Acorda Therapeutics, Inc. (Nasdaq: ACOR) (" Acorda" or the " Offeror") has on 11 March 2016 commenced a voluntary public tender offer (the " Tender Offer") to purchase all of the issued and...